Analytical Cellular Pathology / 2024 / Article / Tab 2 / Review Article
Phospholipase D, a Novel Therapeutic Target Contributes to the Pathogenesis of Neurodegenerative and Neuroimmune Diseases Table 2 Studies on the relationships between PLD and neurodegenerative and neuroimmune diseases.
Study subjects PLD subtypes Main findings Countries/years of publications References AD mouse model PLD3 PLD3 affected axonal spheroids and network defects in AD The USA/2022 [82 ] AD mouse model PLD3 PLD3 was associated with β -amyloid plaques and cognitive function in AD The USA/2021 [83 ] AD patients PLD1 Elevated PLD1 in AD patients’ hippocampus was relevant with synaptic dysfunction and memory deficits The USA/2018 [58 ] AD C. elegans model PLD1 PLD functional ablation had a protective effect in an AD C. elegans model Portugal/2018 [84 ] PD cell model PLD1 PLD1 downregulation might constitute an early mechanism in the initial stages of neurodegeneration Spain/2018 [85 ] PD patients PLD1 PLD1 modulated α -synuclein toxicity China/2022 [69 ] PD mouse model PLD2 The lipase activity of PLD2 was responsible for nigral neurodegeneration in a rat model of PD Spain/2018 [85 ] MS patients PLD1 PLD1 could be used as putative biomarkers for evaluation of therapeutic responses to IFN-β in MS patients. Iran/2017 [86 ] ALS mouse model PLD1/2 PLD1/2 inhibitor could improve ALS phenotype The USA/2022 [73 ] SCA patients PLD3 PLD3 might be a novel gene for SCA The USA/2017 [53 ]
AD, alzheimer’s disease; ALS, amyotrophic lateral sclerosis; IFN-β , interferon-β ; MS, multiple sclerosis; PD, parkinson’s disease; PLD, phospholipase D; SCA, spinocerebellar ataxia; and the USA, the United States of America.